Vivos Therapeutics, Inc.
VVOS- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001716166
No open-market purchases or sales by Vivos Therapeutics, Inc. insiders were filed in the last 90 days; 22 institutions reported holding it in 13F filings for Q2 2026, worth $242.7K in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Vivos Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 16
- −1 vs. Q4 2023
- Shares held
- 136.4K
- +8.17K (+6.4%) vs. Q4 2023
- Total value
- $646.8K
- −$869.6K (−57.3%) vs. Q4 2023
- New holders
- 2
- 3 more added
- Sold out
- 3
- 2 more reduced
1 institution that held it in Q4 2023 haven't filed for Q1 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VVOS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 22 | $242.7K |
| Q1 2026 | 25 | $2.15M |
| Q4 2025 | 20 | $1.34M |
| Q3 2025 | 23 | $2.13M |
| Q2 2025 | 19 | $1.27M |
| Q1 2025 | 21 | $1.00M |
| Q4 2024 | 20 | $2.00M |
| Q3 2024 | 23 | $630.7K |
| Q2 2024 | 19 | $433.8K |
| Q1 2024 | 16 | $646.8K |
| Q4 2023 | 18 | $3.12M |
| Q3 2023 | 28 | $860.6K |
| Q2 2023 | 31 | $2.39M |
| Q1 2023 | 30 | $1.71M |
| Q4 2022 | 27 | $629.7K |
| Q3 2022 | 30 | $1.38M |
| Q2 2022 | 28 | $2.82M |
| Q1 2022 | 28 | $6.66M |
| Q4 2021 | 29 | $5.02M |
| Q3 2021 | 37 | $9.14M |
| Q2 2021 | 29 | $11.7M |
| Q1 2021 | 18 | $5.45M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Vivos Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 103,582 | $500.3K | 0.01% | +46,582+81.7% | Added |
| Commonwealth Equity Services, LLC | 15,000 | $72.0K | 0.00% | +15,000 | New |
| Vanguard Group Inc | 10,579 | $51.1K | 0.00% | 00.0% | Unchanged |
| Newbridge Financial Services Group, Inc. | 1,950 | $9.42K | 0.00% | +655+50.6% | Added |
| Tower Research Capital LLC (TRC) | 1,729 | $8.35K | 0.00% | +11+0.6% | Added |
| Signaturefd, LLC | 547 | $2.64K | 0.00% | 00.0% | Unchanged |
| Group One Trading, L.P. | 228 | $1.10K | 0.00% | −160−41.2% | Reduced |
| Ronald Blue Trust, Inc. | 160 | $773 | 0.00% | −3,840−96.0% | Reduced |
| Bank of America Corp | 80 | $386 | 0.00% | +80 | New |
| Morgan Stanley | 67 | $324 | 0.00% | 00.0% | Unchanged |
| Kozak & Associates, Inc. | 49 | $111 | 0.00% | 00.0% | Unchanged |
| Global Retirement Partners, LLC | 23 | $111 | 0.00% | 00.0% | Unchanged |
| Credit Agricole S A | 2,365 | $63 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 8 | $39 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 7 | $34 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 7 | $0 | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −50,100−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −42−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −12−100.0% | Sold out |
| Strategic Wealth Designers | – | – | – | – | Not filed |